# Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)

> **NCT00151996** · PHASE2 · COMPLETED · sponsor: **Shire** · enrollment: 75 (actual)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity

## Interventions

- **DRUG:** Methylphenidate + SPD503 (Guanfacine hydrochloride)
- **DRUG:** Amphetamine + SPD503

## Key facts

- **NCT ID:** NCT00151996
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08-16
- **Primary completion:** 2004-12-27
- **Final completion:** 2004-12-27
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00151996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00151996, "Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00151996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*